Companies / Israel
Teva Gets Mixed News On Copaxone
March 2006 | Company Finance AlertGenerics giant Teva has reported disappointing trial results for an oral version of its blockbuster proprietary multiple schlerosis drug Copaxone. However, a further delay to the re-introduction of rival therapy Tysabri - developed by Ireland's Elan but withdrawn in February 2005 - could benefit the Israeli firm. However, the search for an orally-delivered, effective MS therapy continues, with both Copaxone and Tysabri only available for intravenous administration.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
